Teva PharmaceuticalsTEVA
About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Employees: 37,851
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
364% more call options, than puts
Call options by funds: $577M | Put options by funds: $124M
156% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 34
23% more repeat investments, than reductions
Existing positions increased: 187 | Existing positions reduced: 152
21% more capital invested
Capital invested by funds: $8.15B [Q1] → $9.89B (+$1.75B) [Q2]
11% more funds holding
Funds holding: 471 [Q1] → 524 (+53) [Q2]
4% more funds holding in top 10
Funds holding in top 10: 24 [Q1] → 25 (+1) [Q2]
2.22% more ownership
Funds ownership: 51.54% [Q1] → 53.77% (+2.22%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
UBS Ashwani Verma 54% 1-year accuracy 7 / 13 met price target | 45%upside $26 | Buy Maintained | 3 Sept 2024 |
Barclays Balaji Prasad 53% 1-year accuracy 16 / 30 met price target | 22%upside $22 | Overweight Maintained | 1 Aug 2024 |
Financial journalist opinion
Based on 14 articles about TEVA published over the past 30 days